DexCom Price Target Increased to $44.00 by Analysts at Benchmark Co. (DXCM)
Investment analysts at Benchmark Co. increased their price target on shares of DexCom (NYSE:DXCM) to $44.00 in a note issued to investors on Tuesday, AR Network reports. Benchmark Co.’s target price would indicate a potential upside of 19.18% from the company’s current price.
A number of other analysts have also recently weighed in on DXCM. Analysts at Wedbush raised their price target on shares of DexCom to $39.00 in a research note to investors on Thursday, November 7th. They now have an “outperform” rating on the stock. Separately, analysts at Raymond James raised their price target on shares of DexCom from $31.00 to $34.00 in a research note to investors on Thursday, November 7th. They now have an “outperform” rating on the stock. Finally, analysts at Northland Capital Partners upgraded shares of DexCom to a “market perform” rating in a research note to investors on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. DexCom presently has an average rating of “Hold” and a consensus target price of $31.47.
DexCom (NYSE:DXCM) traded down 0.89% during mid-day trading on Tuesday, hitting $36.92. 1,020,504 shares of the company’s stock traded hands. DexCom has a 52 week low of $14.05 and a 52 week high of $38.13. The stock has a 50-day moving average of $34.51 and a 200-day moving average of $28.87. The company’s market cap is $2.650 billion.
DexCom, Inc is a medical device company. The Company focuses on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.